![Peter Buckel](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Peter Buckel
Presidente en Vakzine Projekt Management GmbH .
Perfil
Peter Buckel was the founder of Xantos AG, which was founded in 1999, where he held the title of Chief Executive Officer in 2003.
He is currently the Chairman-Supervisory Board at Vakzine Projekt Management GmbH.
Dr. Buckel's former positions include Chief Executive Officer at Atugen AG from 2004 to 2005, Chief Executive Officer at SuppreMol GmbH from 2005 to 2009, and Senior Vice President-Molecular Medicine at Roche Diagnostics GmbH from 1996 to 1999.
Dr. Buckel holds a doctorate from the University of Regensburg, an undergraduate degree from Ludwig-Maximilians-Universität München, and an undergraduate degree from Wuerzburg Schweinfurt University of Applied Sciences.
Cargos activos de Peter Buckel
Empresas | Cargo | Inicio |
---|---|---|
Vakzine Projekt Management GmbH
![]() Vakzine Projekt Management GmbH Pharmaceuticals: MajorHealth Technology Vakzine Projekt Management GmbH develops vaccines and biopharmaceuticals products from laboratory stages through to clinical examination. It offers VPM2001 vaccine to prevent human cytomegalovirus infections and VPM5001 Soluferon vaccine, treatment for multiple sclerosis (MS) and hepatitis C. The company was founded in August 2002 and is headquartered in Hannover, Germany. | Presidente | 16/11/2009 |
Antiguos cargos conocidos de Peter Buckel.
Empresas | Cargo | Fin |
---|---|---|
Atugen AG
![]() Atugen AG Pharmaceuticals: MajorHealth Technology Atugen AG is a biopharmaceutical company. It develops RNAi therapeutics which focus on vivo applications in oncology and liver diseases, exploiting its proprietary oligonucleotide delivery technologies and chemically stabilized siRNA structures. Founded in 1998, the company is headquartered in Berlin, Germany | Presidente | - |
Xantos AG
![]() Xantos AG Pharmaceuticals: MajorHealth Technology Xantos AG is a functional biology and drug discovery company developing biopharmaceuticals in the areas of cancer and metabolic diseases. Its business model is to develop drug discovery pipelines based on the validated targets and leads generated by its proprietary through target identification and validation system and to form indication specific joint research and development collaborations with pharmaceutical and biotechnology companies. It also offers customers its proprietary technology and cDNA/siRNA screening tools for research service deals. The company is headquartered in Munich, Germany. | Fundador | 01/01/2003 |
Roche Diagnostics GmbH
![]() Roche Diagnostics GmbH Miscellaneous Commercial ServicesCommercial Services Part of Roche Holding AG, Roche Diagnostics GmbH is a German company that develops innovative medicines, treatments, and diagnostics. The company is based in Mannheim, Germany. The CEOs of the company are Claudia Fleischer, Claus Haberda, Clemens Schmid. Roche Diagnostics was acquired by Roche Holding AG on January 01, 1999. | Corporate Officer/Principal | 01/01/1999 |
SuppreMol GmbH
![]() SuppreMol GmbH Pharmaceuticals: MajorHealth Technology SuppreMol GmbH engages in the development and use of active substances for the therapy of autoimmune diseases and allergies, as well as the research on and development of medicinal products. It also produces medicines through licensed manufacturers. The products are supplied via pharmaceutical wholesale. The company was founded by Robert Huber, Uwe Jacob, and Peter Sondermann in 2002 and is headquartered in Berlin, Germany. | Presidente | - |
Formación de Peter Buckel.
Ludwig-Maximilians-Universität München | Undergraduate Degree |
Wuerzburg Schweinfurt University of Applied Sciences | Undergraduate Degree |
University of Regensburg | Doctorate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
Empresas privadas | 5 |
---|---|
Atugen AG
![]() Atugen AG Pharmaceuticals: MajorHealth Technology Atugen AG is a biopharmaceutical company. It develops RNAi therapeutics which focus on vivo applications in oncology and liver diseases, exploiting its proprietary oligonucleotide delivery technologies and chemically stabilized siRNA structures. Founded in 1998, the company is headquartered in Berlin, Germany | Health Technology |
SuppreMol GmbH
![]() SuppreMol GmbH Pharmaceuticals: MajorHealth Technology SuppreMol GmbH engages in the development and use of active substances for the therapy of autoimmune diseases and allergies, as well as the research on and development of medicinal products. It also produces medicines through licensed manufacturers. The products are supplied via pharmaceutical wholesale. The company was founded by Robert Huber, Uwe Jacob, and Peter Sondermann in 2002 and is headquartered in Berlin, Germany. | Health Technology |
Xantos AG
![]() Xantos AG Pharmaceuticals: MajorHealth Technology Xantos AG is a functional biology and drug discovery company developing biopharmaceuticals in the areas of cancer and metabolic diseases. Its business model is to develop drug discovery pipelines based on the validated targets and leads generated by its proprietary through target identification and validation system and to form indication specific joint research and development collaborations with pharmaceutical and biotechnology companies. It also offers customers its proprietary technology and cDNA/siRNA screening tools for research service deals. The company is headquartered in Munich, Germany. | Health Technology |
Roche Diagnostics GmbH
![]() Roche Diagnostics GmbH Miscellaneous Commercial ServicesCommercial Services Part of Roche Holding AG, Roche Diagnostics GmbH is a German company that develops innovative medicines, treatments, and diagnostics. The company is based in Mannheim, Germany. The CEOs of the company are Claudia Fleischer, Claus Haberda, Clemens Schmid. Roche Diagnostics was acquired by Roche Holding AG on January 01, 1999. | Commercial Services |
Vakzine Projekt Management GmbH
![]() Vakzine Projekt Management GmbH Pharmaceuticals: MajorHealth Technology Vakzine Projekt Management GmbH develops vaccines and biopharmaceuticals products from laboratory stages through to clinical examination. It offers VPM2001 vaccine to prevent human cytomegalovirus infections and VPM5001 Soluferon vaccine, treatment for multiple sclerosis (MS) and hepatitis C. The company was founded in August 2002 and is headquartered in Hannover, Germany. | Health Technology |
- Bolsa de valores
- Insiders
- Peter Buckel